Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

547
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
547
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Delivering Quadruple Therapy for Heart Failure With Reduced Ejection Fraction in a Customizable Polypill: The COMBO-HF-X Pilot Randomized Trial.

JACC. Heart failure·2026
Same author

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.

Diabetes, obesity & metabolism·2026
Same author

Provider Preferences About a Polypill for Heart Failure With Reduced Ejection Fraction: Development of a Multicenter Physician Survey Containing a Discrete Choice Experiment.

Journal of cardiac failure - intersections·2026
Same author

Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection.

Circulation. Cardiovascular imaging·2026
Same author

Viral respiratory tract infections in heart failure: the FINEARTS-HF trial.

European heart journal·2026
Same author

Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials.

European journal of heart failure·2026

相关实验视频

Updated: Jun 17, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K

心力衰竭与保存的喷射分数的心脏衰竭

Carine E Hamo1, Colette DeJong2, Nick Hartshorne-Evans3

  • 1New York University School of Medicine, Leon H. Charney Division of Cardiology, New York University Langone Health, New York, NY, USA.

Nature reviews. Disease primers
|August 14, 2024
PubMed
概括
此摘要是机器生成的。

保存喷射分数 (HFpEF) 的心力衰竭影响了许多人,尤其是老年人. 管理侧重于指导方针导向的疗法和管理糖尿病和高血压等危险因素,以改善患者的生活质量.

更多相关视频

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.4K

相关实验视频

Last Updated: Jun 17, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.4K

科学领域:

  • 心脏病学 心脏病学
  • 内部医学 内部医学

背景情况:

  • 保存喷射分数 (HFpEF) 的心力衰竭占所有心力衰竭病例的近一半.
  • 由于人口老龄化,其患病率正在增加,导致严重的发病率和死亡率.
  • 关键的危险因素包括年龄,糖尿病,高血压,肥胖和心房动.

研究的目的:

  • 为了提供心力衰竭的全面概述,保留喷射分数 (HFpEF).
  • 讨论HFpEF的多方面的方面,包括其风险因素,病理生理学,诊断和管理.
  • 要突出HFpEF对多个器官系统的影响,并强调未来的研究方向.

主要方法:

  • 关于心力衰竭与保存喷射分数 (HFpEF) 的当前文献的综述.
  • 分析流行病学数据,风险因素和HFpEF的临床表现.
  • 综合有关诊断标准,管理策略和细胞/分子机制的信息.

主要成果:

  • 高FpEF涉及复杂的血液动力学贡献,如腹功能障碍,肺高血压和右心室功能障碍.
  • 细胞和分子变化包括炎症,纤维化,氧化信号受损和线粒体缺陷.
  • HFpEF会影响多个器官系统,包括骨肌肉,肺部,脏和大脑.

结论:

  • 诊断HFpEF需要识别心力衰竭症状,高尿素或拥堵,并排除模仿剂.
  • 管理包括指导方针导向的医疗治疗和综合性并发症管理.
  • 未来的研究应该优先考虑改善HFpEF患者的生活质量.